Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival

Cancer

Volumn 118, Issue 7, 2012, Pages 1795-1802

  Kroeger, Nils ^a   Klatte, Tobias ^a   Birkhäuser, Frédéric D ^a   Rampersaud, Edward N ^a   Seligson, David B ^a   Zomorodian, Nazy ^a   Kabbinavar, Fairooz F ^a   Belldegrun, Arie S ^a   Pantuck, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer specific survival; Immunohistochemistry; Overall survival; p53; Renal cell carcinoma; Smoking; Tissue microarray

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HEART DISEASE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG DISEASE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SMOKING; SURVIVAL ANALYSIS;

EID: 84858703423     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26453     Document Type: Article

References (36)

1. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
2. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004;45(suppl 2):S3-S9. (Pubitemid 39488165)
3. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
4. Parker A, Lohse C, Cheville J, Leibovich B, Igel T, Blute M. Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol. 2008;15:304-308. (Pubitemid 351490145)
5. Yu GP, Ostroff JS, Zhang ZF, Tang J, Schantz SP. Smoking history and cancer patient survival: a hospital cancer registry study. Cancer Detect Prev. 1997;21:497-509. (Pubitemid 27518938)
6. Oh WK, Manola J, Renshaw AA, et al. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology. 2000;55:31-35.
7. Sweeney C, Farrow DC. Differential survival related to smoking among patients with renal cell carcinoma. Epidemiology. 2000;11:344-346. (Pubitemid 30228207)
8. Thrasher JB, Robertson JE, Paulson DF. Expanding indications for conservative renal surgery in renal cell carcinoma. Urology. 1994;43:160-168. (Pubitemid 24065865)
9. Kaelin WG Jr. The p53 gene family. Oncogene. 1999;18: 7701-7705.
10. Noon AP, Vlatkovic N, Polanski R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer. 2010;116:780-790.
11. Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173:725-728. (Pubitemid 40239328)
12. Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:894-900.
13. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res. 2000;6:1840-1844. (Pubitemid 30305080)
14. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10:5464-5471. (Pubitemid 39100484)
15. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004;63:651-655. (Pubitemid 38479402)
16. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114:101-108. (Pubitemid 40194314)
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. (Pubitemid 13149996)
18. American Joint Committee on Cancer. Kidney. In: Sobin LH, Wittekind C, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002:323-325.
19. Fuhrman S, Lasky L, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663. (Pubitemid 13234762)
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847. (Pubitemid 28331029)
21. Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the UCLA integrated staging system for patients with renal cell carcinoma. J Clin Oncol. 2001;19:3792- 3793.
22. Batty GD, Kivimaki M, Gray L, Smith GD, Marmot MG, Shipley MJ. Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study. Ann Oncol. 2008;19:996-1002. (Pubitemid 351627320)
23. Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes D. Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18:2427-2435.
24. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer. 1999;86:2337-2345. (Pubitemid 30010376)
25. Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther. 2010;23:376-383.
26. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372-377. (Pubitemid 37328760)
27. Huang S, Van Arsdall M, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002;94:1134-1142. (Pubitemid 34919050)
28. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2005;23:953-964. (Pubitemid 46202315)
29. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009;41:1452-1462.
30. Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008;113:2457-2463.
31. Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005;65:5076-5083. (Pubitemid 40827316)
32. Chemeris G, Loktinov A, Rempel A, Schwarz M, Bannasch P. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arch. 1995;426:563-569.
33. Zhang XH, Takenaka I, Sato C, Sakamoto H. p53 and HER-2 alterations in renal cell carcinoma. Urology. 1997;50:636-642. (Pubitemid 27433234)
34. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst. 2000;92:803-811. (Pubitemid 30368036)
35. Denissenko MF, Pao A, Pfeifer GP, Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene. 1998;16:1241-1247.
36. Nelson LM, Longstreth WT Jr, Koepsell TD, van Belle G. Proxy respondents in epidemiologic research. Epidemiol Rev. 1990;12:71-86.